AAI Acquires CAC - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

AAI Acquires CAC

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Wilmington, NC (Oct. 26)—AAIPharma Inc. (www.aaipharma.com) completed its acquisition of contract research organization Cvitkovic & Associes Consultants S.A. (CAC, Le Kremlin Bicetre, France). CAC, which specializes in oncology drug development and medical consulting, will form the foundation of AAIOncology, a global business unit dedicated to developing cancer-fighting drugs.

According to Vito Mangiardi, AAI’s president of North American operations, “The experience and expertise brought by our new colleagues in the area of … oncology will significantly strengthen our company’s ability to execute large and global late-stage clinical development programs.”

The acquisition was made possible through a rights offering to existing shareholders and option holders that raised $30 million. The offering was backstopped by a group of principal shareholders led by JPMorgan.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here